Best Biopharma Outsourcing Companies in Boston, United States
The 56 best Biopharma Outsourcing companies in Boston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ventus Therapeutics.
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Boston
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ventus Therapeutics Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment | $300M | 53 mo ago | Series C | — | 2019 | — | 152 patents Small‑molecule inhibitors of NLRP3 inflammasome and related caspase pathways | — |
| 2 | Aiolos Bio Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions | $245M | 32 mo ago | Acquired | Elizabeth Holt Founder and VP | 2023 | — | — | — |
| 3 | Blue Rock Therapeutics Stem cell therapies for cardiovascular and neurological diseases | $225M | 115 mo ago | Acquired | — | 2016 | WordPressApple iCloud MailMySQL+22 | — | — |
| 4 | Superluminal Medicines Generative biological and chemical company focused on drug discovery 57Funding top 21%Talent top 38%Market bottom 44%Partners bottom 35% All 6 signals ▾Fundingtop 21% Talenttop 38% Marketbottom 44% Partnersbottom 35% Globalbottom 29% Newsbottom 15% Funding: Raised $153M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $153M | 11 mo ago | Series A | Ajay Yekkirala Co-Founder | 2022 | — | — | — |
| 5 | Peplib Provider of peptide drug discovery and development services for global pharmaceutical industries | $34M | 62 mo ago | Series A | Li Sean Co-Founder | 2017 | — | — | 4 job openings |
| 6 | Aliada Therapeutics Provider of drug research & development services for multiple therapeutic areas | $33M | 60 mo ago | Acquired | — | 2021 | — | — | — |
| 7 | Meadowhawk Biolabs CRO focused on providing of drug discovery, pharmacology, and bioanalytical services | $20M | 24 mo ago | Series A | — | 2021 | WordPressApple iCloud MailMicrosoft 365+25 | — | — |
| 8 | Xsphera Biosciences Developer of tumor preservation platform | $20M | 49 mo ago | Seed | Steve Remondi Co-Founder & CEO | 2018 | — | — | 1 launch |
| 9 | Dash Bio Provider of automated bioanalysis platform for accelerated clinical drug development 40Talent top 38%Funding top 39%Global bottom 33% All 3 signals ▾Talenttop 38% Fundingtop 39% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $17.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $18M | 13 mo ago | Series A | Ander Tallett Co-Founder & COO | 2024 | — | — | — |
| 10 | Curavit Contract research organization that offers a complete suite of CRO services for decentralized clinical trials | $16M | 44 mo ago | Series A | — | 2019 | WordPressMySQLPHP+29 | — | — |
| 11 | Biosim Provider of contract based drug discovery services | $12M | 29 mo ago | Series B | — | 2020 | — | — | — |
| 12 | Lifordi Biotechnology company developing treatments for autoimmune and inflammatory disorders using antibody-drug… 45Funding top 45%Talent bottom 49%Global bottom 36% All 3 signals ▾Fundingtop 45% Talentbottom 49% Globalbottom 36% Funding: Raised $5.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $6M | 7 mo ago | Seed | Arthur Tzianabos CEO | 2023 | — | — | — |
| 13 | Unravel Biosciences CRO offering early stage clinical development of drugs | $500K | 59 mo ago | Seed | — | 2020 | — | — | — |
Top 12 Biopharma Outsourcing companies in Boston
#1
Series A · Boston, Massachusetts · founded 2022$153Mraised▾
Superluminal Medicines Inc. is a biotechnology research company based in Boston, Massachusetts. They specialize in generative biological and chemical solutions for drug discovery programs. The company recently launched with a $33 million seed round to fuel its drug discovery engine and pipeline of small molecule therapeutics.
- Aug 2025Series A$5M
- Aug 2024Series A$120M
- Aug 2023Seed$33M
#2
Seed · Boston, Massachusetts · founded 2023$5.9Mraised▾
Lifordi is a biotechnology company that develops treatments for autoimmune and inflammatory disorders using antibody-drug conjugates. They have experienced leadership in drug development, immunology, and inflammatory disorders. Lifordi Immunotherapeutics is led by CEO Arthur Tzianabos.
- Nov 2025Seed—
- Sep 2025Grant (prize money)$3M
- Jun 2023Grant (prize money)$3M
#3
Series A · Boston, Massachusetts · founded 2024$17.5Mraised▾
Provider of automated bioanalysis platform for accelerated clinical drug development. It leverages AI and robotics to deliver high-quality assays with faster turnaround times for clinical trials and GLP studies. The company automates critical steps in bioanalysis, reducing costs and time to market. It focuses on clinical bioanalysis, specifically the testing of samples from clinical trial subjects. The platform integrates quality, automation, and regulatory compliance to enhance customer experience and outcomes.
- Jun 2025Series A$11M
- Oct 2024Seed$6.5M
#4
Acquired · Boston, Massachusetts · founded 2023$245Mraised▾
Aiolos Bio is a biotech company focused on developing innovative therapies for respiratory diseases and immune conditions. They recently launched with a $245 million Series A investment to advance the development of their novel Phase 2-ready TSLP antibody.
- Oct 2023Series A$245M
#5
Series A · Boston, Massachusetts · founded 2021 · 35 employees$20.2Mraised▾
CRO focused on providing of drug discovery, pharmacology, and bioanalytical services
- Jul 2024Series A$5M
- Mar 2023Series A$6M
- Aug 2021Series A$9.2M
#6
Series C · Boston, Massachusetts · founded 2019 · 76 employees$300Mraised▾
Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment
- Feb 2022Series C$140M
- Mar 2021Series B$100M
- Nov 2019Series A$60M
#7
Series B · Boston, Massachusetts · founded 2020 · 34 employees$12.2Mraised▾
Developer of a medical technology designed to reduce the timeline for the drug discovery processes. The company's technology uses artificial intelligence to develop a method that can accelerate the drug discovery process, enabling patients and the medical community to discover drugs for diseases considered undruggable.
- Jan 2024Series B$12.2M
#8
Acquired · Boston, Massachusetts · founded 2016 · 138 employees$225Mraised▾
Stem cell therapies for cardiovascular and neurological diseases. It is focused on developing stem cell therapeutics for the treatment of cardiovascular, neurological diseases. Its lead stem cell program is to regenerate heart muscle in patients who have had a heart attack or are suffering from chronic heart failure.
- Dec 2016Series A$225M
#9
Series A · Boston, Massachusetts · founded 2019 · 26 employees$16.4Mraised▾
Curavit Clinical Research is a virtual contract research organization that offers a complete suite of CRO services for decentralized clinical trials. They provide study design, regulatory support, patient enrollment, and a central virtual site for remote monitoring. They also offer Health Economics and Outcomes Research (HEOR) services for digital therapeutic trials.
- Nov 2022Series A$5M
- Sep 2022Series A$11.4M
#10
Seed · Boston, Massachusetts · founded 2018 · 23 employees$20Mraised▾
Developer of tumor preservation platform
- Jun 2022Seed$100K
#11
Acquired · Boston, Massachusetts · founded 2021 · 18 employees$33Mraised▾
Provider of drug research & development services for multiple therapeutic areas
- Jul 2021Seed$33M
#12
Series A · Boston, Massachusetts · founded 2017 · 7 employees$34.2Mraised▾
It is a biotech company that aims to revolutionize peptide drug discovery. They utilize a novel peptide technology platform that uses cyclic peptides to encode and compress information. Peplib provides peptide drug discovery and development services for global pharmaceutical and biotech companies.
- May 2021Series A$34.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Boston is moving
A read on the academic research around Biotechnology in Boston — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 88 papers.
Boston Children's Hospital and Boston University lead RNA modification, splicing, and CRISPR research across 88 papers, with optimistic breakthrough-focused findings slightly tempered by concern.
- Boston Children\'s Hospital35
- Boston University24
- Boston Children\'s Museum9
- University of Massachusetts Boston7
- Boston VA Research Institute5
- Cell biology5
- In vivo5
- Gene4
- RNA-binding protein3
- Messenger RNA3
- Haematopoiesis3
- Somatic cell3
- Epigenetics2
- Disease2
- In vivo2
- Antimicrobial stewardship2
- Psychological intervention2
- In vivo2
- Epidemiology1
- Multidisciplinary approach1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.